ALNY

Alnylam Pharmaceuticals
D

ALNY

266.69
USD
1.73
(0.65%)
Market Closed
Volume
45,133
EPS
-0
Div Yield
-
P/E
-102
Market Cap
34,397,920,755
OverviewSignalsIdeasNews
Related Instruments
    AMGN
    AMGN
    -1.26
    (-0.46%)
    273.59 USD
    A
    ARWR
    -0.050
    (-0.25%)
    19.710 USD
    BIIB
    BIIB
    1.810
    (1.28%)
    142.750 USD
    C
    CRSP
    2.740
    (6.61%)
    44.200 USD
    E
    EDIT
    0.15000
    (12.50%)
    1.35000 USD
    GILD
    GILD
    0.070
    (0.08%)
    93.020 USD
    MRNA
    MRNA
    2.600
    (7.24%)
    38.490 USD
    REGN
    REGN
    -7.47
    (-1.09%)
    679.85 USD
    VRTX
    VRTX
    0.08
    (0.02%)
    428.09 USD
    More
News

Title: Alnylam Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Trading. Social. Simple.
FacebookTwitterYoutube
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHelp Center
Social Network
The NetworkSignals NetworkIdeas NetworkBest Traders
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.